Merck LAPs Up Tilos for Its TGFβ-Targeting Tech

2019 Cancer Discovery  
Merck will spend up to $773 million to acquire Tilos Therapeutics, a 3-year-old startup with a series of preclinical-stage antibodies that prevent the activation and release of TGFβ, a cytokine involved in thwarting the effectiveness of cancer immunotherapies.
doi:10.1158/ pmid:31253722 fatcat:xabivb63xravxjhdwfocr4tl4e